GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition

EP-100 is a synthetic lytic peptide that specifically targets the gonadotropin-releasing hormone receptor on cancer cells. To extend the utility of EP-100, we aimed to identify effective combination therapies with EP-100 for ovarian cancer and explore potential mechanisms of this combination. A seri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Ma, Shaolin, Pradeep, Sunila, Villar-Prados, Alejandro, Wen, Yunfei, Bayraktar, Emine, Mangala, Lingegowda S., Kim, Mark Seungwook, Wu, Sherry Y., Hu, Wei, Rodriguez-Aguayo, Cristian, Leuschner, Carola, Liang, Xiaoyan, Ram, Prahlad T., Schlacher, Katharina, Coleman, Robert L., Sood, Anil K.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497555/
https://ncbi.nlm.nih.gov/pubmed/30926640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0770
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars